Medical Condition News

RSS

DKR Fund for Alzheimer's research launches today

The Darrell K Royal Fund for Alzheimer's Research was launched today at an Interim Joint Committee hearing on Alzheimer's Disease (AD) in the Texas Senate Chamber. The DKR Fund is named after legendary Texas football coach Darrell Royal and was created to facilitate research and care for Texans to attempt to cure AD in our lifetimes.

29 Feb 2012

XL888 inhibitor can prevent vemurafenib resistance in melanoma patients

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

29 Feb 2012

Obesity can decrease risk of mortality in people over 85 years of age

Obesity is considered the leading preventable cause of death worldwide - until you reach old age, that is. Though obesity increases the risk of an early death, shaving an average of six to seven years off a person's lifespan, Tel Aviv University researchers have found that this trend may reverse itself after the age of 85. In these people, excess fat seems to have a "protective" effect, decreasing the risk of death when compared to those who are considered at a normal body weight.

29 Feb 2012

TUT creates first biodegradable joint implant for arthritic patients

Tampere University of Technology (TUT), Finland, has been the first in the world to develop biodegradable joint implant, RegJoint-. The implant is used in the treatment of osteoarthritis and rheumatoid arthritis.

29 Feb 2012

DTMI, Bristol-Myers Squibb partner to broaden interactions

Bristol-Myers Squibb Company and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations.

28 Feb 2012

BrainAble project to offer benefits for people with motor disabilities

In the 2009 film Surrogates, humans live vicariously through robots while safely remaining in their own homes. That sci-fi future is still a long way off, but recent advances in technology, supported by EU funding, are bringing this technology a step closer to reality in order to give disabled people more autonomy and independence than ever before.

28 Feb 2012

Silver Hill Hospital announces opening of Chronic Pain and Addiction Center

Silver Hill Hospital, the nationally recognized psychiatric hospital in New Canaan, CT, announces the opening of the Chronic Pain and Addiction Center, an intensive residential treatment program for patients with pain who have become addicted to opioid medications.

28 Feb 2012

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).

28 Feb 2012

New research shows how motor neurones are produced

The quest for treatments for motor neurone disease, spinal cord injury and strokes could be helped by new research that shows how key cells are produced.

28 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatment of MPS 7

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.

28 Feb 2012

Viewpoints: Disabled 'disdain' a poisonous meme? Two sides on physician payments issue, letting Mich.'s community colleges train nurses

Disability advocates across the political spectrum strongly supported the 2010 health care reform. They had obvious reasons to do so. The new law provides protections for people with preexisting conditions, regulations to make sure insurers properly cover care for chronic illnesses and expanded coverage for young adults and low-income families. But more is at stake here than factual inaccuracies.

28 Feb 2012

Single dose of Ritalin may raise awareness of mistakes: Study

The study, by Dr Rob Hester from the Department of Psychological Sciences and colleagues at the Queensland Brain Institute, investigated how the brain monitors ongoing behavior for performance errors – specifically failures of impulse control. This study found that a single dose of methylphenidate (Ritalin) results in significantly greater activity in the brain’s error monitoring network and improved volunteers’ awareness of their mistakes.

28 Feb 2012

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego.

28 Feb 2012

Stents not more beneficial than medications in stable coronary artery disease: Study

The placement of a stent to repair a narrowed artery in the heart has become routine worldwide. A new analysis of earlier clinical trials shows that inserting a stent has no benefit over standard medical care in treating stable coronary artery disease.

28 Feb 2012

Low levels of omega-3 in blood ‘ups’ risk of dementia and brain aging: Study

Researchers looked at 1,575 adults who averaged 67 years old and had no signs of dementia and had not had a stroke. They were given MRI brain scans and a battery of tests to measure memory and thinking abilities; they also had blood drawn to check the level of docosahexaenoic acid (DHA) or omega-3 fatty acids in their red blood cells. Those with the lowest levels of omega-3s showed signs of accelerated aging. They had lower brain volume, indicating shrinkage comparable to two additional years of aging. Compared with those with the highest blood levels of omega-3s, they scored lower on cognitive tests measuring such things as memory, problem solving, abstract thinking and multi-tasking.

28 Feb 2012